BeStock  

Takeda Pharmaceutical TAK

US equityMarket cap rank #310Infectious Disease
$21.77 +$0.36 (+1.68%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $22.09 +1.47%
Open$21.82
Prev close$21.41
Day range$21.74 – $22.07
Volume3.80M
Market cap$69.76B
P/E (TTM)311.0
Dividend yield1.44%

Earnings

Average move on report day±2.8%last 16 reports
Closed higher7 of 1644% of the time
Best reaction+2.9%
Worst reaction-7.7%

Stock move on the day after each report

-1.5%2024/Q3+2.4%2024/Q4+1.7%2025/Q1+0.4%2025/Q2+2.9%2025/Q3-5.2%2025/Q4-5.0%2026/Q1-3.9%2026/Q2+2.9%2026/Q3+1.3%2026/Q4-2.8%2027/Q1-0.7%2027/Q2
QuarterReport dateTimingImplied moveActual moveVersus implied
2027/Q229 Oct 2026None±6.1%-0.69%Within range
2027/Q130 Jul 2026None±5.8%-2.82%Within range
2026/Q413 May 2026None±10.4%+1.34%Within range
2026/Q329 Jan 2026None±6.1%+2.88%Within range
2026/Q230 Oct 2025None±12.7%-3.92%Within range
2026/Q130 Jul 2025Pre Market±7.6%-5.03%Within range
2025/Q48 May 2025Pre Market±5.3%-5.25%Within range
2025/Q330 Jan 2025Pre Market±5.3%+2.93%Within range
2025/Q231 Oct 2024None±10.2%+0.36%Within range
2025/Q131 Jul 2024Pre Market–+1.69%–
2024/Q49 May 2024None±12.1%+2.37%Within range
2024/Q31 Feb 2024Pre Market±4.1%-1.51%Within range
2024/Q226 Oct 2023None±5.3%-7.72%Bigger than priced
2024/Q127 Jul 2023None±6.7%+1.04%Within range
2023/Q411 May 2023None±6.7%-4.83%Within range
2023/Q32 Feb 2023None±6.6%-0.69%Within range

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Where the revenue comes from

Quarter 2027/Q1

By business line

  • Gastroenterology (GI)¥386.10B 31.7%
  • Plasma Derived Therapies (PDT)¥283.90B 23.3%
  • Rare Diseases¥206.00B 16.9%
  • Oncology¥165.60B 13.6%
  • Neuroscience¥113.60B 9.3%
  • Other¥50.70B 4.2%
  • Vaccines¥14.00B 1.1%

Latest reported quarter: Q2, ended Sep 2026 · reported in JPY

Revenue¥1.19T+6.7% YoY
Operating profit¥285.14B+195.7% YoY
Net profit¥192.46B+1,740.9% YoY
Diluted EPS¥59.49+1,619.5% YoY
Free cash flow¥248.55B-23.6% YoY
Operating cash flow¥304.27B

Revenue, last 8 quarters

¥1.1TDec '24¥1.1TMar '25¥1.1TJun '25¥1.1TSep '25¥1.2TDec '25¥1.1TMar '26¥1.2TJun '26¥1.2TSep '26

Net profit, last 8 quarters

¥23.8BDec '24¥-103.1BMar '25¥124.3BJun '25¥-11.7BSep '25¥103.7BDec '25¥-368.4BMar '26¥113.3BJun '26¥192.5BSep '26

Profitability & balance sheet

Gross margin65.8%
Operating margin14.3%
Net margin0.9%
Return on equity0.6%
Return on assets0.3%
Return on invested capital1.1%
Current ratio1.15
Liabilities / assets51.4%
Cash & investments¥454.40B
Total debt¥4.58T
Net cash (debt)-¥4.12T
Free cash flow / sales9.2%

Discussion

No comments yet — be the first to weigh in on TAK.

Sign in to join the discussion.

Scroll to Top